Home » Posts tagged with » China
CStone Pharmaceuticals strikes $480m worth oncology deal with Pfizer

CStone Pharmaceuticals strikes $480m worth oncology deal with Pfizer

US pharma giant Pfizer has entered into a collaboration deal worth up to $480 million with Chinese biopharma company CStone Pharmaceuticals to address the oncological needs in China. CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and precision medicines for cancer patients. The collaboration will be formed between the Chinese firm and Pfizer’s subsidiaries […]

Chinese biotech company InventisBio raises $147m in Series D round

InventisBio, a Chinese biotech company focused on small molecule drugs, has raised $147 million in a Series D funding round. The funding round of the clinical stage company was led by Hillhouse Capital affiliate GL Ventures. Other new investors are Qiming Venture Partners, Janchor, Matrix Partner China, AIHC Capital, Dyee Capital, and E Fund Capital […]

Continue reading …
SK Biopharmaceuticals launches phase 3 trial of seizures drug cenobamate in Asia

SK Biopharmaceuticals, a South Korean pharma company, has revealed plans to initiate a phase 3 clinical trial for its FDA-approved seizures drug cenobamate in Asia. Cenobamate was approved by the US Food and Drug Administration as an anti-seizure medication (ASM) under the brand name XCOPRI for the treatment of partial-onset seizures in adults. (Read here […]

Continue reading …
Lilly, Innovent Biologics expand licensing deal for blood cancer drug Tyvyt

Eli Lilly and Company has signed an expanded licensing deal worth up to $1 billion with Chinese biotech company Innovent Biologics for their jointly developed Tyvyt (sintilimab injection), an approved blood cancer drug in China. The expanded deal gives the US pharma giant the rights to Tyvyt or geographies outside of China. Innovent Biologics and […]

Continue reading …
G42 Healthcare begins phase 3 trial of Sinopharm COVID-19 inactivated vaccine candidate in UAE

Sinopharm COVID-19 inactivated vaccine candidate : Chinese vaccine manufacturer Sinopharm CNBG has launched a phase 3 trial of its COVID-19 inactivated vaccine candidate, in collaboration with G42 Healthcare, in the UAE. The vaccine developer had found success with the phase 1 and phase 2 clinical trials of the coronavirus vaccine candidate in China. Its vaccine […]

Continue reading …
Chinese regulator accepts NDA of BeiGene’s pamiparib in ovarian cancer

BeiGene said that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a new drug application (NDA) of pamiparib for the treatment of certain ovarian cancer patients. Pamiparib is an investigational inhibitor of PARP1 and PARP2 and its NDA is for patients having deleterious or suspected deleterious germline […]

Continue reading …
Sinovac Biotech gets approval for CoronaVac phase 3 trial in Brazil

CoronaVac phase 3 trial : Sinovac Biotech, a Chinese biopharma company has secured approval in Brazil to begin a phase 3 clinical trial for CoronaVac, its inactivated COVID-19 vaccine candidate. Brazil is currently the second most infected country after the US with the novel coronavirus. The Chinese pharma company has been granted the approval by […]

Continue reading …
China’s CF PharmTech raises $50m in Series F round for inhalation products

CF PharmTech, a Chinese pharma company, has raised $50 million in a Series F financing round to accelerate the commercialization of its inhalation products. The investors who took part in the Series F funding round were BioTrack Capital, CICC Qichen, CICC Qide, Watson Investment, SAIC Hengxu, and GP M&A Fund. The existing investors of CF […]

Continue reading …
Sinovac Biotech CoronaVac COVID-19 vaccine candidate succeeds in phase 1/2 trial

Sinovac Biotech said that the phase 1/2 clinical trial for its coronavirus vaccine candidate CoronaVac has delivered positive preliminary results by showing favorable immunogenicity and safety profiles. According to the Chinese biopharma company, the phase 1/2 clinical trials are randomized, double-blind and placebo-controlled studies featuring 743 healthy volunteers, aged between 18 and 59 years. Of […]

Continue reading …
COVID-19 RT-PCR detection kit : Fosun Pharma secures FDA EUA status

Shanghai Fosun Pharmaceutical (Fosun Pharma) has been granted the emergency use authorization (EUA) status for its COVID-19 RT-PCR detection kit from the US Food and Drug Administration (FDA). Fosun Long March, a fully-owned subsidiary of Fosun Pharma, developed the COVID-19 RT-PCR detection kit which already has a medical device registration certificate from the China National Medical […]

Continue reading …
Page 1 of 41234